The commitments by the Bristol Myers Squibb Foundation build on the more than 100 active grantee projects funded by the Foundation globally to improve access to care and support, and health outcomes that have reached nearly 1.5 million people worldwide. We want every employee to bring their authentic selves to work and to use their diverse perspectives to contribute in a unique and meaningful way to our mission at Bristol Myers Squibb.The mission of the Black Organization for Leadership and Development (BOLD) is to accelerate our business performance at Bristol Myers Squibb by fostering an inclusive environment that values the contributions of Black employees equally with others.

Bristol Myers Squibb and the Bristol Myers Squibb Foundation recognize the need to take concrete steps to better serve and collaborate with an increasingly diverse U.S. population and underserved communities around the world. on New Logo and Identity for Bristol Myers Squibb by Siegel+Gale The group promotes bold leadership and development, encourages involvement in the community and increases cultural awareness across the company.The Bristol Myers Squibb Network of Women (B-NOW) drives business performance by embracing gender diversity. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Download Bristol Myers Squibb Logo transparent PNG Image for free. A federal judge in Maryland said The Johns Hopkins University, Bristol-Myers Squibb Co and the Rockefeller Foundation must face a $1 billion lawsuit over … Five–year commitment builds on long-standing investment in health equity. In addition, any information contained on this website was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. For more information about the Bristol Myers Squibb Foundation, visit us at Bristol Myers Squibb and the Bristol Myers Squibb Foundation Commit $300 Million to Accelerate and Expand Health Equity and Diversity and Inclusion Efforts Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations.

No forward-looking statement can be guaranteed. Learn more about Bristol Myers Squibb and our mission to discover, develop and deliver innovative medicines to patients with serious diseases. Noted Mar. If you worked on this project (as a designer or client) and don’t have a subscription, Brand New, is a division of UnderConsideration, displaying opinions, and focusing solely, on corporate and brand identity work. In recent months, though, COVID-19 has exposed the severity of social and health disparities in the U.S. that increase the risk for infection and poorer health outcomes for Black/African American and Hispanic/Latino communities. The BMS Foundation’s commitment to clinical trial diversity focuses on building clinical trial infrastructure in diverse communities and high disease burden areas in the U.S. and increasing the diversity of investigators through a fellowship program over five years. For more information on these commitments and the work Bristol Myers Squibb is doing to transform patients’ lives through science, visit Each day, our employees around the world work together for patients – it drives everything we do. e are committed to sustaining a culture of inclusion that relies on the diversity of people and on unique perspectives and experience to achieve our patient-focused mission and business objectives. Exelixis, Inc. (NASDAQ:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the initiation of the phase 3 CheckMate 9ER trial to evaluate Opdivo ® (nivolumab) in combination with CABOMETYX (cabozantinib) tablets, a small molecule inhibitor of receptor tyrosine kinases, or Opdivo and Yervoy ® (ipilimumab) in combination with CABOMETYX versus sunitinib in patients with … In 2016, we invested $4.9 billion in R&D, which included the discovery and development of new medicines. These documents are available from the Securities and Exchange Commission, the Bristol Myers Squibb website or from Bristol Myers Squibb Investor Relations.Learn more about how we strive to produce sustained strong performance and shareholder value.Click investor alerts to manage event, presentation and SEC Filing email notifications, or  select press release alerts to subscribe to company news alerts.Acquisition-Related Information for Celgene Shareholders When choosing between competing products and services, please consider our advertisers, who help support Brand New. These documents are available from the Securities and Exchange Commission, the Bristol Myers Squibb website or from Bristol Myers Squibb Investor Relations. For more information about Bristol Myers Squibb, visit us at IMAGE: Bristol Myers Squibb logo view more Credit: Bristol Myers Squibb (New York) July 16, 2020 - Stand Up To Cancer today announced a new $5 million grant from Bristol Myers Squibb …